Stroke: Analysis of the efficacy of the treatment of large vascular thrombosis patients with venous thrombosis

Evidence from a growing number of randomized controlled clinical trials suggests that inepase may replace the effective treatment of isosterase for acute ischemic stroke.
Recently, in a research paper published in the authoritative journal Stroke in the field of cardiovascular disease, researchers tried to compare the efficacy and safety of venous venous ternine and intravenous administration of atipase in patients with acute ischemic stroke large vascular thrombosis.
researchers searched the MEDLINE and Scopus databases for published randomized controlled clinical trials that provided outcomes in patients with acute ischemic stroke and were diagnosed with LVO and received different doses of sterols or standard doses of 0.9 mg/kg atipase.
result of the study was the chance of improving the Rankin scale score to 0 to 2 at 3 months.
researchers included four randomized controlled clinical trials in 433 patients.
ranked LVO patients treated with tynepase with an improved Rankin scale score of 0 to 2 (ratio ratio of 2.06 (95% CI is 1.15-3.69)), re-pass success (ratio of 3.05 (95% CI is 1). .73-5.40) and functional improvements (all improved Rankin Scale scores were reduced by 1 point (common ratio ratio of 1.84 (95% CI is 1.18-2.87)) are more likely than in patients with LVO treated with atipase.
the results provided by the study of these outcomes were almost heterogeneic (I2≤20%).
There was no difference in early neurological improvement, symptomatic intracranial bleeding, any intracranial bleeding, and improved Rankin Scale scores of 0 to 1 or 3 months in patients with LVO who received intravenous thrombosis therapy of sterolase.
, it can be seen that LVO acute ischemic stroke patients treated with venous aptide are significantly improved and clinically effective compared to patients treated with venous aptidease.
。